menu
    • menu
    [{"orgOrder":0,"company":"Merz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Winhealth Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"concentrate for solution for infusion","sponsorNew":"Merz Pharma \/ Winhealth Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Winhealth Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Teijin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"Ach","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Merz Therapeutics"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Incobotulinumtoxin A","moa":"Ach release","graph1":"Dermatology","graph2":"Approved","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharma \/ Merz Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Merz Pharma

    Menu

    Merz Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Acorda Therapeutics

                            Deal Size : $185.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merz Enters Asset Purchase Agreement With a US-based Biotech Company

                            Details : Merz Therapeutics will acquire Acorda's assets, including Inbrija (levodopa inhalation) for OFF episodes in Parkinson’s and Ampyra (dalfampridine).

                            Brand Name : Inbrija

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 02, 2024

                            Lead Product(s) : Etilevodopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Acorda Therapeutics

                            Deal Size : $185.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merz Aesthetics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Merz Aesthetics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Merz Aesthetics to Showcase New Data at the 20th Aesthetics & Anti-Aging Medicine World Congress 2022

                            Details : Study Design of LONG RUN: A LONGitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants, demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines

                            Brand Name : Xeomin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XEOMIN® (incobotulinumtoxinA) Receives European Approval for the Treatment of Chronic Sialorrhea in Children

                            Details : The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Sialorrhea Pediatric Xeomin Investigation).

                            Brand Name : Xeomin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Teijin Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin ® From Merz

                            Details : Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.

                            Brand Name : Xeomin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 23, 2021

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Teijin Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Ornithine L-aspartate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved

                            Sponsor : Winhealth Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China

                            Details : The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.

                            Brand Name : Hepa-Merz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 08, 2021

                            Lead Product(s) : L-Ornithine L-aspartate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved

                            Sponsor : Winhealth Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Merz Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Health Canada Licenses XEOMIN® (incobotulinumtoxinA) for Adult Patients With Sialorrhea

                            Details : XEOMIN was licensed by Health Canada for adult patients with sialorrhea on the basis of a Phase III, randomized, double-blind, placebo-controlled, multicenter trial in which 184 patients participated.

                            Brand Name : Xeomin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 01, 2020

                            Lead Product(s) : IncobotulinumtoxinA

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth